AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD
Grazia Pennisi(University of Palermo), Salvatore Petta(Department of Health), Adele Tulone(University of Palermo), Ciro Celsa(Hammersmith Hospital), Michela Antonucci(University of Palermo), Claudia La Mantia(University of Palermo), V. Di Marco(University of Palermo), Giuseppe Infantino(University of Palermo), Stefanie Parisi(University of Palermo), Carlo Ciccioli(University of Palermo), Marco Enea(University of Palermo), Calogero Cammà(University of Palermo), Antonio Craxı̀(University of Palermo), Alessandra Pandolfo(University of Palermo)
Cited by 83
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
|Hepatology|2017|657